GENTAMICIN SULFATE- gentamicin sulfate solution/ drops A-S Medication Solutions

Gentamicin Sulfate Ophthalmic Solution, USP 0.3% (Sterile) Rx only

DESCRIPTION

Gentamicin sulfate ophthalmic solution, USP is a sterile, aqueous solution buffered to approximately pH 7.0 and formulated for ophthalmic use.

Each mL contains:


Active: gentamicin sulfate, USP (equivalent to 3 mg gentamicin).

Inactives: dibasic sodium phosphate, sodium chloride, monobasic sodium phosphate, purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.5 - 7.5).

Preservative: benzalkonium chloride 0.01%.

Gentamicin is an aminoglycoside antibiotic obtained from cultures of *Micromonospora purpurea*. It is a mixture of the sulfate salts of gentamicin C1, C2, C1a and C2a. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol.

The structural formula is as follows:



CLINICAL PHARMACOLOGY

Microbiology

Gentamicin sulfate is active *in vitro* against many strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE

Gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS

Gentamicin sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

NOT FOR INJECTION INTO THE EYE

Gentamicin sulfate ophthalmic solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

General

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician. If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy

Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

ADVERSE REACTIONS

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

Instill one or two drops into the affected eye(s) every four hours. In severe infections dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

Product: 50090-0569

NDC: 50090-0569-0 5 mL in a BOTTLE, DROPPER / 1 in a CARTON

Gentamicin Sulfate

Prod	0090-056 uct No	4355-	-0
	ICIN SULFA	re	
SOLUTIO			1
GENTAMIC TO 3 MG C STORE E DEGREE	CONTAINS: ACT CIN SULFATE, US ISNTAMICIN, BETWEEN 36 S F. AVOID E ESSIVE HEAT	SP (EQUIVALEN TO 77 EXPOSURE	
5 ML			
	DOSAGE: SEE GTIN: 0035 LOT: EXP: S/N:	PACKAGE INSERT 0090056907	7
	dication Solut lie, IL 60048	lions	RX ON

Ρ	roduct Info	rmation					
P	roduct Type		HUMAN PRESCRIPTION DRUG	ltem Code (Source)			
R	oute of Admir	nistration	OPHTHALMIC				
A	ctive Ingred	lient/Active	Moiety				
	Ingredient Name Basis of Strength				ength	Strength	
G	ENTAMICIN SUL	-	386QRLV) (GENTAMICIN - UN	II:T6Z9V48IKG			3 mg in 1 ml
Ir	nactive Ingr	edients	Ingradiant Nama				Strongth
Ingredient Name Strength SODIUM CHLORIDE (UNII: 451W47IQ8X) Strength						Strength	
			SIC, UNSPECIFIED FORM	UNII: 3980JIH2	5W)		
	ATER (UNII: 059			. ,			
H١	YDROCHLORIC	ACID (UNII: QTT	L7582CB)				
		(IDE (UNII: 55X04					
		CHLORIDE (UNII					
SC	DDIUM PHOSPH	IATE, DIBASIC,	UNSPECIFIED FORM (UNII:	GR686LBA74)			
P	ackaging						
#	ltem Code	Pa	ackage Description	M	arketing Start Date	Marl	keting End Date
1	NDC:50090- 0569-0	1 in 1 CARTON		06/2	29/2016		
1		5 mL in 1 BOTT Combination Pro	LE, DROPPER; Type 0: Not a				

Marketing Information						
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
ANDA	ANDA064048	05/11/1994				

Labeler - A-S Medication Solutions (830016429)

Establishment					
Name	Address	ID/FEI	Business Operations		
A-S Medication Solutions		830016429	RELABEL(50090-0569)		

Revised: 5/2023

A-S Medication Solutions